Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Molecular Signatures of Cutaneous Dupilumab Response

ID
Name
21-35748
Description
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Trial arms
Trial start
2023-02-01
Estimated PCD
2026-02-01
Trial end
2026-02-01
Status
Recruiting
Phase
Early phase I
Treatment
Dupilumab
dupilumab
Arms:
dupilumab treatment
Size
15
Primary endpoint
Change in Eczema Area and Severity Index (EASI) score from baseline to 8-12 weeks
baseline and 8-12 weeks
Eligibility criteria
Inclusion Criteria: 1. 18 years of age or older 2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7 Exclusion Criteria: 1. Known pregnancy 2. Known immunodeficiencies 3. Known parasitic infection -
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 15, 'type': 'ESTIMATED'}}
Updated at
2023-05-15

1 organization

1 product

1 indication

Organization
University of California, San Francisco
Product
Dupilumab
Indication
Atopic Dermatitis